Hospitals Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway byJosh SandbergNovember 29, 2018
Biologics Hospitals Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway byJosh SandbergNovember 1, 2018
Hospitals Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway byJosh SandbergSeptember 27, 2018
Biologics Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage byJosh SandbergSeptember 6, 2018
Financial Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results byJosh SandbergAugust 10, 2018
Biologics Hospitals Histogenics Agreement With Japan Pharmaceuticals and Medical Devices Agency and Regulatory Pathway for NeoCart® byJosh SandbergMay 8, 2017
Biologics Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing byJosh SandbergMarch 10, 2017
Biologics Histogenics Corporation to Present at Upcoming Investor Conferences byJosh SandbergFebruary 24, 2017
Sports Medicine Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine byJosh SandbergJanuary 16, 2017
Financial Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results byJosh SandbergAugust 11, 2016
